DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Cut to $14.00 by Analysts at Mizuho

Key Points

• Mizuho cut its price target on DENTSPLY SIRONA to $14 (from $16) and maintained a "neutral" rating, a level that implies roughly a 23.8% upside from the stock's recent ~$11.31 price; the Street consensus is an average "Hold" with a $13.73 target.
• The company reported Q1 revenue of $880M that beat estimates but posted adjusted EPS of $0.27 (missed by $0.01) and a GAAP loss, while FY‑2026 EPS guidance of $1.40–$1.50 was broadly in line amid ongoing margin pressure from U.S. softness, tariffs and transformation costs.
• Insiders bought a total of 70,000 shares last quarter and institutional/hedge fund ownership is extremely high (~95.7%), with several large funds materially increasing positions.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) had its price target cut by equities research analysts at Mizuho from $16.00 to $14.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the medical instruments supplier's stock. Mizuho's price target would indicate a potential upside of 23.84% from the stock's current price.

Several other research firms also recently commented on XRAY. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, February 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. Robert W. Baird upped their price target on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a "neutral" rating in a research note on Friday, February 27th. Wells Fargo & Company increased their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 27th. Finally, Barrington Research raised their price objective on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an "outperform" rating in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, DENTSPLY SIRONA has an average rating of "Hold" and a consensus price target of $13.73.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.31 on Wednesday. DENTSPLY SIRONA has a 12-month low of $9.85 and a 12-month high of $17.18. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -3.79, a P/E/G ratio of 1.32 and a beta of 0.93. The stock's 50 day moving average price is $12.14 and its two-hundred day moving average price is $12.02. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $880.00 million for the quarter, compared to the consensus estimate of $841.80 million. During the same quarter in the prior year, the firm posted $0.43 earnings per share. The business's revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts anticipate that DENTSPLY SIRONA will post 1.43 earnings per share for the current year.

Insider Activity

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the company's stock in a transaction on Monday, March 9th. The stock was acquired at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the purchase, the director directly owned 10,000 shares of the company's stock, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory T. Lucier acquired 15,000 shares of the business's stock in a transaction on Monday, March 9th. The stock was acquired at an average cost of $12.45 per share, with a total value of $186,750.00. Following the acquisition, the director directly owned 65,000 shares in the company, valued at approximately $809,250. This trade represents a 30.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 70,000 shares of company stock valued at $956,437 in the last quarter. Corporate insiders own 0.52% of the company's stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its holdings in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock worth $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Armistice Capital LLC raised its stake in DENTSPLY SIRONA by 1,044.0% in the third quarter. Armistice Capital LLC now owns 5,736,000 shares of the medical instruments supplier's stock valued at $72,790,000 after purchasing an additional 5,234,587 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in DENTSPLY SIRONA by 662.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 4,608,341 shares of the medical instruments supplier's stock worth $58,480,000 after purchasing an additional 4,003,606 shares during the period. Goldman Sachs Group Inc. lifted its position in DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the period. Finally, Marshall Wace LLP grew its stake in DENTSPLY SIRONA by 1,032.5% during the fourth quarter. Marshall Wace LLP now owns 2,236,786 shares of the medical instruments supplier's stock worth $25,566,000 after buying an additional 2,039,280 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and top-line strength: Dentsply reported Q1 net sales of $880M vs. consensus ~$842M, surprising on the top line even as EPS missed, supporting near-term revenue momentum. Dentsply Sirona beats Q1 sales expectations
• Positive Sentiment: New product — AI-enabled diagnostic: Company launched Smart View‑Detect (FDA-cleared, CE-marked), an AI diagnostic aid for CBCT scans — a potential multi-market growth driver for imaging and software revenue over time. Smart View - Detect launch
• Positive Sentiment: U.S. distribution expansion and early commercial traction: Enhanced agreement with Atlanta Dental Supply (adds a channel for connected technology) and first CEREC install under new Benco deal signal expanding go-to-market reach for consumables and equipment. Distribution expansion with Atlanta Dental Supply
• Neutral Sentiment: FY‑2026 guidance roughly in-line on EPS but revenue range mixed vs Street: Company gave FY EPS of $1.40–$1.50 (Street ~1.43) and revenue $3.5–3.6B (slightly below some estimates) — guidance reduces uncertainty but isn’t a strong catalyst either way. Q1 results & guidance (press release/slide deck)
• Neutral Sentiment: Analyst positioning: Brokers show an average “Hold” and coverage notes stabilization but not a clear re-rating event yet — suggests limited near-term upside until margin/growth trends clarify. Average recommendation of "Hold"
• Negative Sentiment: EPS miss and GAAP loss: Reported adjusted EPS $0.27 (miss by $0.01) and GAAP net loss per share ($0.05); EPS is down from $0.43 year‑ago, putting pressure on near-term sentiment and valuation. Q1 EPS miss
• Negative Sentiment: Margin pressure, tariffs and transformation costs remain a concern: Management flagged U.S. softness, tariff headwinds and transformation costs that weigh on margins — investors will watch margin recovery and working capital / debt reduction execution. Analyst preview: margin & tariff risks

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.